Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Psycheceutical
Deal Size : $10.5 million
Deal Type : Acquisition
Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences
Details : Vici is an end-to-end pharmaceutical research and development company specializing in taking projects from pre-clinical research through the Phase 2 stage of FDA approval.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $10.5 million
August 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Psycheceutical
Deal Size : $10.5 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?